ECSP088484A - Derivados de quinazolina espirocíclicos como inhibidores de pde7 - Google Patents

Derivados de quinazolina espirocíclicos como inhibidores de pde7

Info

Publication number
ECSP088484A
ECSP088484A EC2008008484A ECSP088484A ECSP088484A EC SP088484 A ECSP088484 A EC SP088484A EC 2008008484 A EC2008008484 A EC 2008008484A EC SP088484 A ECSP088484 A EC SP088484A EC SP088484 A ECSP088484 A EC SP088484A
Authority
EC
Ecuador
Prior art keywords
pde7 inhibitors
spirocyclic
quinazoline derivatives
pain
compounds
Prior art date
Application number
EC2008008484A
Other languages
English (en)
Inventor
David James Rawson
Nigel Alan Swain
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of ECSP088484A publication Critical patent/ECSP088484A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Abstract

La invención proporciona compuestos de fórmula (I): consta gráfico en la que; m es 0, 1 ó 2; X es 0, S o N-CN; R es F, CI o CN; A es un grupo cicloalquileno C3-6 opcionalmente sustituido con un grupo alquilo C1-14; y B es un enlace sencillo o un grupo alquileno C1-2 o una de sus sales, solvatos, polimorfisimos o profármacos farmacéuticamente aceptable. Los compuestos son inhibidores de PDE7 y tiene una diversidad de aplicaciones terapéuticas, particularmente en el tratamiento del dolor, especialmente dolor neuropático.
EC2008008484A 2005-12-02 2008-05-29 Derivados de quinazolina espirocíclicos como inhibidores de pde7 ECSP088484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74185405P 2005-12-02 2005-12-02
US79118606P 2006-04-10 2006-04-10

Publications (1)

Publication Number Publication Date
ECSP088484A true ECSP088484A (es) 2008-06-30

Family

ID=37882213

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008484A ECSP088484A (es) 2005-12-02 2008-05-29 Derivados de quinazolina espirocíclicos como inhibidores de pde7

Country Status (22)

Country Link
US (1) US7507742B2 (es)
EP (1) EP1957467A2 (es)
JP (1) JP2009517453A (es)
KR (1) KR101009554B1 (es)
AP (1) AP2008004470A0 (es)
AR (1) AR058266A1 (es)
AU (1) AU2006321349A1 (es)
BR (1) BRPI0619126A2 (es)
CA (1) CA2631535C (es)
CR (1) CR10039A (es)
EA (1) EA200801145A1 (es)
EC (1) ECSP088484A (es)
GT (1) GT200600494A (es)
MA (1) MA30014B1 (es)
ME (1) MEP0408A (es)
NL (1) NL2000336C2 (es)
NO (1) NO20082077L (es)
PE (1) PE20071087A1 (es)
RS (1) RS20080233A (es)
TW (1) TW200732307A (es)
UY (1) UY29979A1 (es)
WO (1) WO2007063391A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
AP2007004161A0 (en) * 2005-04-28 2007-10-31 Pfizer Ltd Amino acid derivatives
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
AU2008230710B2 (en) * 2007-03-27 2014-04-10 Omeros Corporation The use of PDE7 inhibitors for the treatment of movement disorders
WO2008142550A2 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic derivatives
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
TWI546537B (zh) * 2009-05-19 2016-08-21 維維亞生技公司 提供針對血液腫瘤之體外個人化藥物測試之方法
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX2020000295A (es) * 2017-07-12 2020-07-22 Dart Neuroscience Llc Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407604A1 (en) 2000-04-28 2001-11-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Splice variant of camp phosphodiesterase type 7 (pde7a3)
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CA2599662A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain

Also Published As

Publication number Publication date
TW200732307A (en) 2007-09-01
MA30014B1 (fr) 2008-12-01
US7507742B2 (en) 2009-03-24
AP2008004470A0 (en) 2008-06-30
CA2631535C (en) 2010-07-27
AU2006321349A1 (en) 2007-06-07
RS20080233A (en) 2009-07-15
EA200801145A1 (ru) 2008-10-30
WO2007063391A2 (en) 2007-06-07
UY29979A1 (es) 2007-06-29
GT200600494A (es) 2007-07-06
JP2009517453A (ja) 2009-04-30
KR20080059338A (ko) 2008-06-26
NL2000336C2 (nl) 2007-08-07
US20070129388A1 (en) 2007-06-07
KR101009554B1 (ko) 2011-01-18
WO2007063391A3 (en) 2007-09-13
AR058266A1 (es) 2008-01-30
PE20071087A1 (es) 2007-12-29
CA2631535A1 (en) 2007-06-07
NO20082077L (no) 2008-06-04
CR10039A (es) 2008-07-10
MEP0408A (xx) 2010-02-10
EP1957467A2 (en) 2008-08-20
BRPI0619126A2 (pt) 2011-09-13
NL2000336A1 (nl) 2007-06-05

Similar Documents

Publication Publication Date Title
ECSP088484A (es) Derivados de quinazolina espirocíclicos como inhibidores de pde7
NI201200059A (es) PIPERIDINAS SUSTITUIDAS QUE AUMENTAN LA ACTIVIDAD DE p53 Y SUS USOS
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ECSP056127A (es) Inhibidores de 3-quinasa de fosfatidil-inositol
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
UY29633A1 (es) Derivados de oxindol
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
SE0302811D0 (sv) Novel compounds
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
ECSP109953A (es) Derivados de piridazinona
UY29246A1 (es) Nuevos compuestos
NO20073783L (no) Pyrrolidininhibitorer for IAP
ECSP066958A (es) Compuestos de morfolina
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia
NO20081292L (no) Pentasykliske kinaseinhibitorer
NO20091495L (no) Pyrazolopyrimidinderivat
EA200701366A1 (ru) Кислородсодержащие аннелированные фенилпиперазин- и фенилдиазепанкарбоксамиды
GT200500016A (es) Compuestos de quinolina sustituidos